Literature DB >> 16299104

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

Alexandre Havt1, Andrew V Schally, Gabor Halmos, Jozsef L Varga, Gabor L Toller, Judit E Horvath, Karoly Szepeshazi, Frank Köster, Kevin Kovitz, Kate Groot, Marta Zarandi, Celia A Kanashiro.   

Abstract

Various attempts to detect human pituitary growth hormone-releasing hormone receptor (pGHRH-R) in neoplastic extrapituitary tissues have thus far failed. Recently, four splice variants (SVs) of GHRH-R have been described, of which SV1 has the highest structural homology to pGHRH-R and likely plays a role in tumor growth. The aim of this study was to reinvestigate whether human tumors and normal human extrapituitary tissues express the pGHRH-R and to corroborate our previous findings on its SVs. Thus, we developed a real-time PCR method for the detection of the mRNA for the pGHRH-R, its SVs, and the GHRH peptide. Using real-time PCR, Western blotting, and radioligand-binding assays, we detected the mRNA for pGHRH-R and pGHRH-R protein in various human cancer cell lines grown in nude mice and in surgical specimens of human lung cancers. The expression of mRNA for SVs of pGHRH-R and GHRH was likewise found in xenografts of human non-Hodgkin's lymphomas, pancreatic cancer, glioblastoma, small-cell lung carcinomas, and in human nonmalignant prostate, liver, lung, kidney, and pituitary. Western blots showed that these normal and malignant human tissues contain SV1 protein and immunoreactive GHRH. Our results demonstrate that some normal human tissues and tumors express mRNA and protein for the pGHRH-R and its splice variants. These findings confirm and extend the concept that GHRH and its receptors play an important role in the pathophysiology of human cancers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299104      PMCID: PMC1297670          DOI: 10.1073/pnas.0506844102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.

Authors:  Z Rekasi; J L Varga; A V Schally; G Halmos; P Armatis; K Groot; T Czompoly
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

2.  The mutant growth hormone-releasing hormone (GHRH) receptor of the little mouse does not bind GHRH.

Authors:  B D Gaylinn; V I Dealmeida; C E Lyons; K C Wu; K E Mayo; M O Thorner
Journal:  Endocrinology       Date:  1999-11       Impact factor: 4.736

3.  Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice.

Authors:  Z Kahán; J L Varga; A V Schally; Z Rékási; P Armatis; L Chatzistamou; T Czömpöly; G Halmos
Journal:  Breast Cancer Res Treat       Date:  2000-03       Impact factor: 4.872

4.  Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours.

Authors:  Simona Freddi; Giorgio Arnaldi; Francesca Fazioli; Marina Scarpelli; Gloria Appolloni; Tatiana Mancini; Blerina Kola; Xavier Bertagna; Franco Mantero; Robert Collu; Marco Boscaro
Journal:  Clin Endocrinol (Oxf)       Date:  2005-05       Impact factor: 3.478

Review 5.  Hypothalamic hormones and cancer.

Authors:  A V Schally; A M Comaru-Schally; A Nagy; M Kovacs; K Szepeshazi; A Plonowski; J L Varga; G Halmos
Journal:  Front Neuroendocrinol       Date:  2001-10       Impact factor: 8.606

6.  A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines.

Authors:  L K Chopin; A C Herington
Journal:  Prostate       Date:  2001-10-01       Impact factor: 4.104

7.  Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs.

Authors:  Hippokratis Kiaris; Andrew V Schally; Rebeca Busto; Gabor Halmos; Spyros Artavanis-Tsakonas; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

8.  The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.

Authors:  M Olga Garcia-Fernandez; Andrew V Schally; Jozsef L Varga; Kate Groot; Rebeca Busto
Journal:  Breast Cancer Res Treat       Date:  2003-01       Impact factor: 4.872

9.  Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity.

Authors:  K Groot; J E Horvàth; R Z Cai; A V Schally
Journal:  Int J Pept Protein Res       Date:  1995-06

Review 10.  Peptides and growth factors in non-small cell lung cancer.

Authors:  T W Moody
Journal:  Peptides       Date:  1996       Impact factor: 3.750

View more
  42 in total

1.  Possible predictors of histopathological response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Robert Farkas; Eva Pozsgai; Andrew V Schally; Andras Szigeti; Edit Szigeti; Zoltan Laszlo; Andras Papp; Eva Gomori; Laszlo Mangel; Peter O Horvath; Szabolcs Bellyei
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-08       Impact factor: 4.553

2.  Discrimination between alternate membrane protein topologies in living cells using GFP/YFP tagging and pH exchange.

Authors:  Beatriz Domingo; María Gasset; Mario Durán-Prado; Justo P Castaño; Antonio Serrano; Thierry Fischer; Juan Llopis
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

3.  Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases.

Authors:  Ferenc G Rick; Andrew V Schally; Luca Szalontay; Norman L Block; Karoly Szepeshazi; Mehrdad Nadji; Marta Zarandi; Florian Hohla; Stefan Buchholz; Stephan Seitz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-18       Impact factor: 11.205

4.  Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene.

Authors:  Carla R P Oliveira; Roberto Salvatori; Luciana M A Nóbrega; Erick O M Carvalho; Menilson Menezes; Catarine T Farias; Allan V O Britto; Rossana M C Pereira; Manuel H Aguiar-Oliveira
Journal:  Clin Endocrinol (Oxf)       Date:  2008-07-01       Impact factor: 3.478

Review 5.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

6.  Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.

Authors:  Nektarios Barabutis; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

7.  GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer.

Authors:  Ferenc G Rick; Stephan Seitz; Andrew V Schally; Luca Szalontay; Awtar Krishan; Christian Datz; Andreas Stadlmayr; Stefan Buchholz; Norman L Block; Florian Hohla
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

8.  A glimpse at growth hormone-releasing hormone cosmos.

Authors:  Nektarios Barabutis
Journal:  Clin Exp Pharmacol Physiol       Date:  2020-04-25       Impact factor: 2.557

9.  Antagonist of GH-releasing hormone receptors alleviates experimental ocular inflammation.

Authors:  Yong Jie Qin; Sun On Chan; Kelvin Kam Lung Chong; Benjamin Fuk Loi Li; Tsz Kin Ng; Yolanda Wong Ying Yip; Haoyu Chen; Mingzhi Zhang; Norman L Block; Herman S Cheung; Andrew V Schally; Chi Pui Pang
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

10.  Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.

Authors:  Luca Szalontay; Andrew V Schally; Petra Popovics; Irving Vidaurre; Awtar Krishan; Marta Zarandi; Ren-Zhi Cai; Anna Klukovits; Norman L Block; Ferenc G Rick
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.